Oxaliplatin Injection shortage
To Be Discontinued 6 presentations · 3 manufacturers · first FDA posting 2025-10-20 · last update 2026-06-29
Manufacturers: Fresenius Kabi USA, LLC, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Sandoz Inc.
Stated reasons (per FDA): Not stated
Presentations
| Presentation | Manufacturer | Status | Reason | Notes (FDA) | Dates |
|---|---|---|---|---|---|
| Oxaliplatin, Injection, 5 mg/mL (NDC 63323-750-10) | Fresenius Kabi USA, LLC | To Be Discontinued | — | A business decision was made to discontinue manufacture of the drug. | Posted 02/25/2026 Updated 02/25/2026 Discontinued 02/25/2026 |
| Oxaliplatin, Injection, 5 mg/mL (NDC 63323-750-20) | Fresenius Kabi USA, LLC | To Be Discontinued | — | A business decision was made to discontinue manufacture of the drug. | Posted 02/25/2026 Updated 02/25/2026 Discontinued 02/25/2026 |
| Oxaliplatin, Injection, 5 mg/1 mL (NDC 25021-233-10) | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | To Be Discontinued | — | Marketed by Sagent Pharmaceuticals; Discontinuation of the manufacture of the drug | Posted 06/29/2026 Updated 06/29/2026 Discontinued 06/29/2026 |
| Oxaliplatin, Injection, 5 mg/1 mL (NDC 25021-233-20) | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | To Be Discontinued | — | Marketed by Sagent Pharmaceuticals; Discontinuation of the manufacture of the drug | Posted 06/29/2026 Updated 06/29/2026 Discontinued 06/29/2026 |
| Oxaliplatin, Injection, 5 mg/1 mL (NDC 0781-3315-70) | Sandoz Inc. | To Be Discontinued | — | Discontinuation of the manufacture of the drug | Posted 10/20/2025 Updated 10/20/2025 Discontinued 10/20/2025 |
| Oxaliplatin, Injection, 5 mg/1 mL (NDC 0781-3317-80) | Sandoz Inc. | To Be Discontinued | — | Discontinuation of the manufacture of the drug | Posted 10/20/2025 Updated 10/20/2025 Discontinued 10/20/2025 |
Get the weekly shortage roundup: a free email of FDA shortage changes (open form)